Product Code: GVR-3-68038-980-7
Heart Failure POC And LOC Devices Market Growth & Trends:
The global heart failure POC and LOC devices market size is expected to reach USD 284.9 million by 2030 and is projected to grow at a CAGR of 16.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.. A paradigm shift in diagnostic sectors from late-stage disease detection to early identification of diseases as a viable strategy to curb rising healthcare costs has driven the market. This shift has led to the development of disposable and low-cost LOC devices that integrate various sensors and associated accessories in a single space for detection of the cardiac biomarkers from a single specimen to evaluate the risk of having a heart attack.
Furthermore, the development of predictive modeling techniques-based decision support software to analyze the data measured by the LOC assays to enable therapy monitoring is one of the key market drivers. Also, ongoing studies on the application of saliva-based nano-biochip tests for measuring myocardial infarction is driving organic revenue growth.
POC testing exhibits potential savings across various settings, including hospitals, general practice, and remote areas. In the U.S., the employment of POC devices resulted in a 20% decrease in hospital admissions to the chest pain unit, resulting in substantial savings in time and costs.
In the cardiac observation unit (U.S.), the implementation of POC troponin testing helped reduce hospital stays, decrease admission rates, and remove the need for multiple costly procedures, resulting in 25% cost saving per patient. Furthermore, the integration of smartphones and apps in POC diagnostics for managing the cardiac health of an individual is one of the significant innovations in Heart Failure POC & LOC Devices market.
Heart Failure POC And LOC Devices Market Report Highlights:
- Proteomic analysis includes products that test protein markers, such as troponin, myoglobin, and Creatine Kinase MB Isoenzyme (CK-MB)
- This segment accounted for the leading revenue share, as most of the currently available products are based on testing of protein markers
- Increasing implementation of microfluidic LOC technology for assessing putative biomarkers has led to the largest revenue share of this technology
- Microfluidic technologyhas been implemented for various biological applications, such as immunohybridization techniques, enzymatic assays, PCR, and others
- Clinics that include physician's office, pharmacy & retail clinics, urgent care clinics, and non-practice clinics are the key revenue generating end-users
- A high usage rate of POC devices by general practitioners for rapid investigation, deciding early treatment, timely referral, and less uncertainty for patients has driven the revenue growth through clinics
- The U.S. dominated the global Heart Failure POC & LOC devices market owing to the presence of a substantial number of primary care clinics that are deploying POC cardiac marker test as a measure for early detection of heart failure
- Expanding urbanization and increasing geriatric population underpin the demand for robust and improved healthcare services such as POC diagnostics for routine cardiac health monitoring in Asian countries
- Moreover, initiatives are undertaken for training young healthcare personnel about POC cardiac troponin T/cardiac troponin I biomarkers
- This, in turn, is anticipated to result in the surging adoption rate of POC devices in Asian countries
- Abbott, Siemens Healthineers, Danahar, and F. Hoffmann-La Roche Ltd are some key participants operating in the space
- Companies are engaged in mergers and acquisitions of emerging players. Acquisition of Alere by Abbott, Beckman Coulter, Inc by Danahar, and Accriva Diagnostics by Instrumentation Laboratory are some examples of acquisitions in this market
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Test type
- 1.1.2. Technology
- 1.1.3. End use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Test type outlook
- 2.2.2. Technology outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Heart Failure POC & LOC Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Heart Failure POC & LOC Devices Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Heart Failure POC & LOC Devices: Test Type Estimates & Trend Analysis
- 4.1. Heart Failure POC & LOC Devices Market: Key Takeaways
- 4.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Proteomic Testing
- 4.3.1. Proteomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Metabolomic Testing
- 4.4.1. Metabolomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Genomic Testing
- 4.5.1. Genomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Heart Failure POC & LOC Devices: Technology Estimates & Trend Analysis
- 5.1. Heart Failure POC & LOC Devices Market: Key Takeaways
- 5.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Microfluidics
- 5.3.1. Microfluidics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Array-based Systems
- 5.4.1. Array-based systems market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Heart Failure POC & LOC Devices: End Use Estimates & Trend Analysis
- 6.1. Heart Failure POC & LOC Devices Market: Key Takeaways
- 6.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Clinics
- 6.3.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Hospitals
- 6.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Home
- 6.5.1. Home market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Assisted Living Healthcare Facilities
- 6.6.1. Assisted living healthcare facilities market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.7. Laboratory
- 6.7.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Heart Failure POC & LOC Devices Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Heart Failure POC & LOC Devices Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Abbott Laboratories
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Siemens Healthineers
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Danaher
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Instrumentation Laboratory
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. F. Hoffmann-La Roche Ltd.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. bioMerieux S.A.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Abaxis, Inc.
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Quidel Corporation
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Jant Pharmacal Corporation
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiative
- 8.2.10. Trinity Biotech
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives